Summary & Overview
HCPCS J0841: Injection of Crotalidae Immune F(ab')2 (Equine), 120 mg
HCPCS Level II code J0841 denotes administration of crotalidae immune F(ab')2 (equine), 120 mg — an antivenom used to treat crotaline (pit viper) envenomation. This code captures the biologic product itself for use in acute care settings where rapid neutralization of venom is clinically necessary. Nationally, antivenom therapy represents a high-acuity, episodic expense with implications for emergency and inpatient clinical workflows, inventory management, and payer coverage policies.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and clinical context for use. The publication also summarizes payer coverage patterns and billing considerations, common modifier usage, and where to look for related procedural and diagnosis coding when documenting antivenom administration. Finally, readers will find benchmarks and policy updates relevant to hospital and emergency department billing for high-cost biologic agents in acute settings. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0841 represents an injection of crotalidae immune F(ab')2 (equine), 120 mg. This medication is an antivenom derived from equine antibodies and is used for the treatment of envenomation from crotaline (pit viper) snakebites.
-
Service type: Therapeutic biologic injection
-
Typical site of service: Emergency department, inpatient hospital, or other acute care settings where management of venomous snakebite and serum administration is provided
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient presenting after a venomous snakebite or with systemic signs suggestive of crotaline envenomation (rattlesnake, copperhead, cottonmouth). Initial evaluation occurs in an emergency department or urgent care setting where triage includes airway, breathing, circulation assessment, neurovascular exam of the bitten extremity, serial limb measurements, coagulation studies, complete blood count, basic metabolic panel, and baseline creatine kinase. When clinical signs progress—such as expanding local swelling, progressive ecchymosis, hypotension, neurotoxic signs, coagulopathy, or laboratory evidence of hemolysis—administration of antivenom is indicated.
The billing code J0841 denotes injection of crotalidae immune F(ab')2 (equine), 120 mg. Typical site of service is the emergency department, inpatient ward (medical/surgical), or observation unit; administration occurs in a monitored clinical area with intravenous access, resuscitation equipment, and staff trained in anaphylaxis management. Dosing and number of vials follow product-specific protocols; patients are observed for infusion reactions and for progression of envenomation with repeat exams and labs. Documentation includes indication, time of dose, lot number, route (intravenous), number of vials, patient response, and any adjunctive therapies (analgesia, tetanus update, wound care).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |